Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
1 Cathie Wood Stock That Could Deliver Life-Changing Returns in 10 Years
07:45am, Thursday, 30'th Nov 2023
Cathie Wood is known for investing in cutting-edge innovators. Her ARK Genomic Revolution ETF owns several gene-editing companies, but Prime Medicine might be the best of the bunch.
Prime Medicine to Present at Upcoming Investor Conferences
08:00am, Wednesday, 08'th Nov 2023
Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic therap
7 Biotech Stocks to Get In Now Before Investors Catch On
02:50am, Monday, 23'rd Oct 2023
Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
Prime Medicine: Not Yet Primed For Retail Investment
08:49am, Wednesday, 27'th Sep 2023
Prime Medicine is developing prime editing, a highly precise gene editing technology that offers advantages over traditional CRISPR-Cas9 gene editing. Prime editing has shown promising results in huma
2 Cathie Wood Stocks That Could Be Hidden Gems
07:45am, Tuesday, 25'th Jul 2023
Cathie Wood has positions in several leading genomic medicine companies. Prime Medicine and Ginkgo Bioworks could be two of her fund's biggest winners in the years to come.
Cathie Wood Goes Bargain-Hunting: 3 Stocks She Just Bought
10:15am, Friday, 02'nd Jun 2023
CrowdStrike, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. CrowdStrike opened 8% lower on Thursday despite a "beat and raise" quarterly report.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:45am, Friday, 26'th May 2023
UiPath, Prime Medicine, and Adaptive Biotechnologies were all on the Ark Invest shopping list on Thursday. Wood was particularly hungry for UiPath, adding shares of the robotics enterprise software sp
Prime Medicine to Present at Virtual Investor Conferences in May
04:05pm, Wednesday, 17'th May 2023
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
06:00am, Wednesday, 17'th May 2023
Data demonstrated Prime Editors efficiently, reproducibly and durably corrected the causative mutation of CGD, supporting advancement of development candidate PM359
Prime Medicine: Gene Editing Tech With Unique Approach
09:10am, Sunday, 23'rd Apr 2023
Prime Medicine: Gene Editing Tech With Unique Approach.
Prime Medicine to Present at Guggenheim Healthcare Talks – Genomic Medicines and Rare Disease Days
08:00am, Monday, 27'th Mar 2023
CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap
Prime Medicine to Present at Cowen 43rd Annual Health Care Conference
08:00am, Monday, 27'th Feb 2023
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
12:15am, Thursday, 12'th Jan 2023
CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't
10 Potential 10x Return Stocks For The Next 10 Years
11:04am, Wednesday, 04'th Jan 2023
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or i
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
08:00am, Tuesday, 03'rd Jan 2023
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
